BMS’ Orencia gets FDA nod for GvHD thanks to real-world dataBristol-Myers Squibb’s rheumatoid arthritis drug Orencia has been approved by the FDA to prevent graft versus host disease Share XBMS’ Orencia gets FDA nod for GvHD thanks to real-world datahttps://pharmaphorum.com/news/bms-orencia-gets-fda-nod-for-gvhd-thanks-to-real-world-data/
AZ files for emergency use of COVID-19 antibody combo in USAstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent Share XAZ files for emergency use of COVID-19 antibody combo in UShttps://pharmaphorum.com/news/az-files-for-emergency-use-of-covid-antibody-combo-in-us/
AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clashAbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Share XAbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clashhttps://pharmaphorum.com/news/abbvies-qulipta-cleared-for-migraine-prevention-setting-up-biohaven-clash/
AZ’s COVID jab tackles delta variant, but antibody fails clinical trialThe delta variant of COVID-19 may be holding back the lifting of lockdown restrictions in the UK, but Share XAZ’s COVID jab tackles delta variant, but antibody fails clinical trialhttps://pharmaphorum.com/news/azs-covid-jab-tackles-delta-variant-but-antibody-fails-clinical-trial/
Novartis’ Aimovig tops topiramate in migraine face-offNovartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to Share XNovartis’ Aimovig tops topiramate in migraine face-offhttps://pharmaphorum.com/news/novartis-aimovig-tops-topiramate-in-migraine-face-off/
Non-vaccine nasal spray could protect against COVID-19Two UK biotechs – Destiny Pharma and Sporegen – have joined forces to develop a nasal spray that Share XNon-vaccine nasal spray could protect against COVID-19https://pharmaphorum.com/news/non-vaccine-nasal-spray-could-protect-against-covid-19/
Chasing Regeneron, AZ starts trials of its COVID-19 antibody cocktailThe first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that Share XChasing Regeneron, AZ starts trials of its COVID-19 antibody cocktailhttps://pharmaphorum.com/news/chasing-regeneron-az-starts-trials-of-its-covid-19-antibody-cocktail/
Personalised digital health: A tool, not a silver bulletDigital health tech has the potential to help us all live longer, healthier lives – but it isn’t Share XPersonalised digital health: A tool, not a silver bullethttps://pharmaphorum.com/digital/personalised-digital-health-a-tool-not-a-silver-bullet/
Roche’s Xofluza limits spread of flu virus, says new studyRoche’s new influenza drug Xofluza can dramatically prevent the spread of the virus when used as a preventive Share XRoche’s Xofluza limits spread of flu virus, says new studyhttps://pharmaphorum.com/news/roches-xofluza-limits-spread-of-flu-virus-says-new-study/
